Luzitin is a privately owned pharmaceutical company, focused on the development of innovative photosensitizer compounds for Photodynamic Therapy (PDT) or diagnosis (PDx) of cancer and other diseases.
Founded in 2010, Luzitin emerged as a spin-off company from a collaboration beteen Bluepharma, and the University of Coimbra. Its most advanced project (LUZ11) is currently in Phase IIa clinical trials in the treatment of solid tumors.
|
|
|
PRODUCTS & SERVICES
Luzitin is developing a promising therapeutic procedure for solid tumors. The technology consists of a combination of new generation photosensitizer (LUZ11) with a specific infrared-laser medical device.
The main benefits are: high efficacy; easy to use; absence of systemic adverse effects; cost-effective.
In vivo studies indicate that, in addition to its strong cytotoxic and vascular effects, this therapeutic approach leads to significant antitumor immune response, thus hampering metastatic processes to occur. The therapeutic protocol consists of a 30 min procedure and can be conducted at an outpatient basis. No skin phototoxicity is observed both at indoor and at outdoor light.
Due to its benefits and advantages over existing therapeutic approaches, LUZ11 presents unique features to be a first line therapy for solid tumors accessible by light, including pre-cancerous lesions. LUZ11 already has promising phase II clinical data, clearly reinforcing the favorable PK properties, convenience of use, safety profile and efficacy previously demonstrated in non-clinical studies.
Recently, Luzitin has achieved a very relevant asset, an Orphan Medicinal Product Designation for the treatment of Biliary Tract Cancer, a Life-threatening and chronically debilitating condition. Submission of EMA Scientific advice and FDA IND application are planned for summer of 2015.
Due to its benefits and advantages over existing therapeutic approaches, LUZ11 presents unique features to be a first line therapy for solid tumors accessible by light, including pre-cancerous lesions.
LUZ11 already has promising phase II clinical data on Safety and Tolerability, Pharmacokinetics and Efficacy.
|
|
TARGET MARKETS / CLIENTS
Our main compound (LUZ11) aims at the worldwide market.
At this stage Luzitin is looking for partnerships in order to further proceed on the clinical development of our technology, with:
/Pharmaceutical Industry:
Companies with the potential to In-Licensing Luzitin pipeline products.
/Investment companies: Investors (focus in Venture Capital) with an investment profile that fits Luzitin.
|
